A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer




TekijätValta MP, Zhao HJ, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimaki J, Harkonen P, Coleman I, Nelson PS, Corey E, Peehl DM

KustantajaSPRINGER

Julkaisuvuosi2016

JournalClinical and Experimental Metastasis

Tietokannassa oleva lehden nimiCLINICAL & EXPERIMENTAL METASTASIS

Lehden akronyymiCLIN EXP METASTAS

Vuosikerta33

Numero4

Aloitussivu325

Lopetussivu337

Sivujen määrä13

ISSN0262-0898

eISSN1573-7276

DOIhttps://doi.org/10.1007/s10585-016-9781-2


Tiivistelmä

LuCaP serially transplantable patient-derived xenografts (PDXs) are valuable preclinical models of locally advanced or metastatic prostate cancer. Using spheroid culture methodology, we recently established cell lines from several LuCaP PDXs. Here, we characterized in depth the features of xenografts derived from LuCaP 136 spheroid cultures and found faithful retention of the phenotype of the original PDX. In vitro culture enabled luciferase transfection into LuCaP 136 spheroids, facilitating in vivo imaging. We showed that LuCaP 136 spheroids formed intratibial, orthotopic, and subcutaneous tumors when re-introduced into mice. Intratibial tumors responded to castration and were highly osteosclerotic. LuCaP 136 is a realistic in vitro-in vivo preclinical model of a subtype of bone metastatic prostate cancer.




Last updated on 2024-26-11 at 14:24